Amgen, Inc. (AMGN) EVP Sean E. Harper Sells 1,525 Shares

Amgen, Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Amgen, Inc. (AMGN) opened at $187.72 on Thursday. Amgen, Inc. has a one year low of $150.38 and a one year high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05. The firm has a market cap of $136,270.00, a price-to-earnings ratio of 16.96, a PEG ratio of 2.71 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same period in the prior year, the business posted $3.02 earnings per share. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. research analysts predict that Amgen, Inc. will post 12.71 EPS for the current fiscal year.

Amgen declared that its board has authorized a share buyback program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.81%. Amgen’s dividend payout ratio is 41.55%.

AMGN has been the subject of a number of recent research reports. BMO Capital Markets reiterated a “market perform” rating and set a $198.00 price objective on shares of Amgen in a research report on Thursday, October 26th. Mizuho reiterated a “buy” rating and set a $198.00 price objective (up previously from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. BidaskClub upgraded Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $196.00 price objective (up previously from $189.00) on shares of Amgen in a research report on Friday, October 6th. Fifteen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $190.15.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Baker Ellis Asset Management LLC acquired a new position in Amgen during the third quarter worth $108,000. Phocas Financial Corp. acquired a new position in Amgen during the second quarter worth $110,000. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the last quarter. Omnia Family Wealth LLC increased its position in Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after buying an additional 147 shares during the last quarter. Finally, Grove Bank & Trust increased its position in Amgen by 87.4% during the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after buying an additional 341 shares during the last quarter. 78.48% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.truebluetribune.com/2018/01/18/amgen-inc-amgn-evp-sean-e-harper-sells-1525-shares.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply